The robust efficacy across PD-L1 subgroups and manageable safety profile de-risk pumitamig's Phase 3 program. Monitor upcoming data from Phase 3 trials (ROSETTA Lung-02, Lung-201, Lung-202) and potential regulatory filings. The partnership with BMS provides strong commercial infrastructure. Near-term catalyst: further Phase 3 readouts in NSCLC and other indications.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $91.70entry
- T+1 · 6mo ago −2.79%α −2.94% · $89.14
- T+5 · 5mo ago −3.95%α −1.20% · $88.08
- T+20 · 5mo ago +1.47%α +2.77% · $93.05
- T+60 · 3mo ago +24.37%α +23.14% · $114.05
Price Chart
How similar events traded
Executive Summary
BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in first-line NSCLC at ASCO 2026. The data showed high confirmed objective response rates (cORR) of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose, with 100% disease control rate and manageable safety. This supports the ongoing Phase 3 program and positions pumitamig as a potential new standard of care across PD-L1 expression levels.
Key Facts
- Interim Phase 2 data from ROSETTA Lung-02 trial (NCT06712316) presented at ASCO 2026
- cORR of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower 1400 mg dose
- 100% disease control rate (DCR) across all evaluable patients
- cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%)
- Grade ≥3 treatment-related adverse events in 48.8% of patients; pumitamig-related in 23.3%
- Treatment discontinuation due to AEs in 4 patients (9.3%)
- Phase 3 part of ROSETTA Lung-02 actively enrolling; two additional global Phase 3 trials in NSCLC ongoing
- Seven global Phase 3 trials with registrational potential currently ongoing across multiple indications
Financial Impact
No financial figures provided; clinical data supports potential multi-billion-dollar peak sales opportunity if approved in first-line NSCLC, a large market (~85% of lung cancer cases)
Risk Factors
- Phase 3 trials may fail to replicate Phase 2 efficacy or show unexpected safety signals
- Competition from existing PD-(L)1 inhibitors and other bispecifics in development
- Regulatory approval not guaranteed; manufacturing and commercial execution risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303897 |
Track record
38 reports on BNTX
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers